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TO THE EDITOR
Regarding our publication in the Sep-
tember issue of this journal (Vergilis
et al., 2005), our purpose was to find a
serological marker that was present in
early- as well as late-stage melanoma.
Our study showed that the marker CYT-
MAA was detectable in the serum of
61% of patients and its presence
correlated with a poorer prognosis,
regardless of disease stage. At the same
time, we evaluated the marker HMW-
MAA (also known as melanoma-asso-
ciated chondroitin sulfate proteoglycan)
in the serum of the same patients.
Ulmer et al. (2004) suggest (see letter
in this issue) that the presence of the
HMW-MAA may be related to the
presence of circulating melanoma cells
that express that antigen. This is
certainly possible, as we have pre-
viously shown that circulating melano-
ma cells are present in patients with
resected melanoma (Bystryn et al.,
2000), and that their presence is related
to treatment and to the clinical out-
come of the patients (Reynolds et al.,
2003). On the other hand, HMW-MAA
is shed by melanoma cells, so that the
presence of this antigen in the circula-
tion could also reflect residual tumor
burden. The differences in the expres-
sion of HMW-MAA and the stage of
disease between our study and that of
Ulmer et al. (2004) may, among other
causes, be owing to the differences in
the type of patients that were studied,
their prior treatment, and the assays
themselves.
It is clear from our study (Vergilis
et al., 2005) that assays can be devel-
oped to measure serological markers in
patients who have melanoma that has
not yet progressed to stage IV disease.
Which method and marker alone or
combination will prove to be the most
sensitive remains to be determined.
Thus, studying combinations of mar-
kers, as suggested by Ulmer et al., is
certainly a good idea. However, we no
longer study circulating melanoma cells
as their measurement is more difficult
than measuring melanoma antigens and
requires special handling of blood, which
is difficult to do in clinical practice.
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